Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

493
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
493
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

448
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
448
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

1.3K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.3K
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

770
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
770
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

831
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
831
Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

210
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
210

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Series 2: Invisible Threats: A Global Scoping Review of Risk Factors for Tuberculosis Infection.

Tropical medicine and infectious disease·2026
Same author

Series 3: From Infection to Disease: A Global Scoping Review of Medical and Behavioural Determinants of Progression from TB Infection to TB Disease.

Tropical medicine and infectious disease·2026
Same author

Air conditioning, ventilation, and respiratory virus transmission potential in South India.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026
Same author

Series 1: Behind the Spread: A Scoping Review of Risk Factors for Exposure to <i>Mycobacterium tuberculosis</i>.

Tropical medicine and infectious disease·2026
Same author

Accuracy and Acceptability of the VISITECT CD4 Advanced Disease Test Compared With the PIMA CD4 Test at the Point of Care as Part of the Advanced HIV Disease Care Package: A Mixed-Methods Study.

Open forum infectious diseases·2026
Same author

Feasibility and efficacy of a population-based pulmonary rehabilitation for post-tuberculosis lung disease in Bangladesh.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026

Related Experiment Video

Updated: Jan 1, 2026

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
23:06

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis

Published on: August 11, 2008

19.5K

Short-Course Regimen for Multidrug-Resistant Tuberculosis: A Decade of Evidence.

Arnaud Trébucq1, Tom Decroo2,3, Armand Van Deun4

  • 1International Union Against Tuberculosis and Lung Disease, 75006 Paris, France.

Journal of Clinical Medicine
|December 29, 2019
PubMed
Summary

Short multidrug-resistant tuberculosis (MDR-TB) regimens, particularly the Bangladesh regimen, show over 80% success. Gatifloxacin is the most effective fluoroquinolone, and its essential medicine status should be restored.

Keywords:
9-month regimenMDRfluoroquinolonesoutcome analysistreatmenttuberculosis

More Related Videos

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

8.2K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

9.0K

Related Experiment Videos

Last Updated: Jan 1, 2026

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
23:06

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis

Published on: August 11, 2008

19.5K
A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

8.2K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

9.0K

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Global Health

Background:

  • The Bangladesh regimen, a 9-month treatment for multidrug-resistant tuberculosis (MDR-TB), revolutionized treatment protocols.
  • Subsequent short MDR-TB regimens utilized later-generation fluoroquinolones like gatifloxacin, moxifloxacin, or levofloxacin.

Purpose of the Study:

  • To review published data on short MDR-TB regimens.
  • To analyze their efficacy, composition, and safety in diverse settings.
  • To assess their current relevance against new World Health Organization (WHO) guidelines.

Main Methods:

  • Systematic review of published literature on short MDR-TB treatment regimens.
  • Analysis of treatment outcomes, adverse events, and fluoroquinolone resistance.
  • Comparison with longer treatment regimens and WHO recommendations.

Main Results:

  • Short MDR-TB regimens achieved over 80% success rates, significantly outperforming longer regimens (around 50%).
  • Gatifloxacin emerged as the most effective fluoroquinolone in these regimens.
  • Adverse event monitoring is crucial for regimen adaptation and preventing severe side effects like deafness.

Conclusions:

  • Short-term MDR-TB regimens offer superior efficacy compared to longer protocols.
  • Gatifloxacin demonstrates the highest effectiveness but is not currently an essential medicine.
  • Restoring gatifloxacin's essential medicine status is a priority for optimizing MDR-TB treatment.